latam

Regístrate
Invertir conlleva riesgos y puede no ser adecuado para todos los inversores.
Inicio・Lista de Acciones・AstraZeneca PLC
Search

AstraZeneca PLC

Cerrado

Sector Salud

12,406 -2.07

Comprar

Precios actualizados 10 sept 2024, 15:29 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

11798

Máximo

12712

Métricas clave

By Trading Economics

Ingresos

-252M

1.9B

Ventas

258M

13B

P/B

Media del Sector

38.58

103.001

BPA

1.98

Margen de beneficio

14.894

EBITDA

-349M

4.1B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+6.35 upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

16M

205B

Apertura anterior

12408.07

Cierre anterior

12406

Noticias sobre sentimiento de mercado

By Acuity

37%

63%

80 / 365 Clasificación en Healthcare

AstraZeneca PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

25 jul 2024, 09:17 UTC

Ganancias

AstraZeneca Raises Guidance After Results Beat Market Expectations -- Update

DJ

Leer

25 jul 2024, 06:48 UTC

Ganancias

AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations

DJ

Leer

9 sept 2024, 07:56 UTC

Charlas de Mercado

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

DJ

Leer

5 sept 2024, 13:00 UTC

Principales Noticias

China Detains AstraZeneca Employees Over Alleged Transport of Unapproved Drug -- WSJ

DJ

Leer

29 jul 2024, 10:30 UTC

Principales Noticias

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

DJ

Leer

25 jul 2024, 13:20 UTC

Ganancias

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

DJ

Leer

25 jul 2024, 09:21 UTC

Charlas de Mercado
Ganancias

AstraZeneca's Guidance Lift Is Conservative; Risks to Upside -- Market Talk

DJ

Leer

25 jul 2024, 07:05 UTC

Charlas de Mercado
Ganancias

AstraZeneca Guidance Raise Signals Portfolio Potential -- Market Talk

DJ

Leer

25 jul 2024, 06:06 UTC

Ganancias

AstraZeneca Increased Interim Dividend by 7c to $1.00

DJ

Leer

25 jul 2024, 06:04 UTC

Ganancias

AstraZeneca Had Seen Core EPS Grow by Low Double-Digit to Low Teens Percentage Range

DJ

Leer

25 jul 2024, 06:04 UTC

Ganancias

AstraZeneca Had Seen Total Revenue Grow by Low Double-Digit to Low Teens Percentage Range

DJ

Leer

25 jul 2024, 06:04 UTC

Ganancias

AstraZeneca Sees Core EPS Growth in 2024 by Mid Teens Percentage Range At Constant Currency

DJ

Leer

25 jul 2024, 06:04 UTC

Ganancias

AstraZeneca Sees Total Revenue Growth in 2024 by Mid Teens Percentage Range At Constant Currency

DJ

Leer

25 jul 2024, 06:03 UTC

Ganancias

AstraZeneca Raises 2024 View

DJ

Leer

25 jul 2024, 06:02 UTC

Ganancias

AstraZeneca 2Q Revenue Consensus Was $12.7B

DJ

Leer

25 jul 2024, 06:02 UTC

Ganancias

AstraZeneca 2Q Core EPS Consensus Was $1.95

DJ

Leer

25 jul 2024, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Adj EPS $1.98

DJ

Leer

25 jul 2024, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Pretax Pft $2.4B

DJ

Leer

25 jul 2024, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Rev $12.94B

DJ

Leer

25 jul 2024, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Oper Pft $2.75B

DJ

Leer

25 jul 2024, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Net Pft $1.93B

DJ

Leer

25 jul 2024, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q EPS $1.24

DJ

Leer

15 jul 2024, 06:04 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone

DJ

Leer

15 jul 2024, 06:04 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone

DJ

Leer

15 jul 2024, 06:02 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca: Acquisition Includes $800M Upfront at Deal Closing

DJ

Leer

15 jul 2024, 06:02 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca: Amolyt Pharma's Total Consideration of Up to $1.05B

DJ

Leer

15 jul 2024, 06:01 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca: Acquisition Bolsters Alexion Rare Disease Late-Stage Pipeline

DJ

Leer

15 jul 2024, 06:00 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca Completes Acquisition of Amolyt Pharma

DJ

Leer

15 jul 2024, 06:00 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca PLC Acquisition of Amolyt Pharma completed

DJ

Leer

15 jul 2024, 06:00 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca PLC Acquisition of Amolyt Pharma completed

DJ

Leer

AstraZeneca PLC Esperado

Precio Objetivo

By TipRanks

6.35% repunte

Estimación a 12 meses

Media 13,519.57 GBX  6.35%

Máximo 15,914 GBX

Mínimo 11,000 GBX

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

16 ratings

11

Comprar

4

Mantener

1

Vender

De acuerdo con 16 analistas que ofrecen calificaciones bursátiles a para AstraZeneca PLC Dist en los últimos 3 meses.

Sentimiento

By Acuity

80 / 365 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

$

Acerca de AstraZeneca PLC

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.